{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T11:08:29Z","timestamp":1723201709483},"reference-count":9,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.clinthera.2009.11.025","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T04:59:17Z","timestamp":1264481957000},"page":"2722-2734","source":"Crossref","is-referenced-by-count":6,"title":["Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: Four open-label, randomized crossover trials in healthy volunteers"],"prefix":"10.1016","volume":"31","author":[{"given":"Clinton W.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Aikman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Werts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Seabolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc C.","family":"Haeusler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.11.025_bib1","series-title":"(venlafaxine hydrochloride) extended-release capsules [package insert]","author":"Effexor","year":"2009"},{"key":"10.1016\/j.clinthera.2009.11.025_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-0327(98)00222-5","article-title":"Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion","volume":"51","author":"Horst","year":"1998","journal-title":"J Affect Disord."},{"key":"10.1016\/j.clinthera.2009.11.025_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/106002809502900410","article-title":"Venlafaxine: A structurally unique and novel antidepressant","volume":"29","author":"Morton","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2009.11.025_bib4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2165\/00003495-199549020-00010","article-title":"Venlafaxine. A review of its pharmacology and therapeutic potential in depression","volume":"49","author":"Holliday","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2009.11.025_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.57.5.503","article-title":"Evidence of the dual mechanisms of action of venlafaxine","volume":"57","author":"Harvey","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2009.11.025_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0011-393X(97)80042-2","article-title":"Pharmacokinetics of once-daily venlafaxine extended release (ER) in healthy volunteers","volume":"58","author":"Troy","year":"1997","journal-title":"Curr Ther Res Clin Exp."},{"key":"10.1016\/j.clinthera.2009.11.025_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/j.1552-4604.1998.tb04423.x","article-title":"Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects","volume":"38","author":"Patat","year":"1998","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.11.025_bib8","series-title":"Venlafaxine extended release tablets [package insert]","year":"2009"},{"issue":"Suppl 18","key":"10.1016\/j.clinthera.2009.11.025_bib11","first-page":"14","article-title":"Immediate-release versus controlled-release formulations: Pharmacokinetics of newer antidepressants in relation to nausea","volume":"64","author":"DeVane","year":"2003","journal-title":"J Clin Psychiatry"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T06:13:20Z","timestamp":1558764800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809004159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0149291809004159"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.025","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}